Previous 10 | Next 10 |
2023-04-05 13:10:09 ET Summary The month of March had a couple of very interesting insider purchases. In this article, we discuss some of the biggest insider purchases by value. In addition, we will take a look into 2 companies more in-depth, which we found particularly intere...
The Ohio State University-led study will evaluate changes in CRC screening adherence in underserved urban and rural communities Guardant Health is providing Shield ™ blood test to eligible individuals through mobile health clinic partners Guardant Health, Inc. (Na...
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. RED DEER, AB / ACCESSWIRE / March 16, 2023 / Gamehost Inc. (‘Gamehost', the ‘Company') (TSX:GH) Effective April 1, 2023 to March 31, 2025, AGLC is temporarily increasing the slot commission...
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. RED DEER, AB / ACCESSWIRE / March 14, 2023 / Gamehost Inc. (TSX:GH) Management and Directors of Gamehost Inc. (the "Company") present results for the twelve and three months ended December 31, 2022 (the...
2023-03-10 08:25:20 ET Guardant Health ( NASDAQ: GH ) submitted the final module of a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Shield, a blood test to screen colorectal cancer (CRC). The filing consists of ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for Shield ™ , Guardant Health’s blood test to screen for c...
Summary Guardant Health has continued a revenue increase as showcased in the last earnings report, growing 17% YoY. GH stock is part of a large industry that has high CAGR estimates, but investors are yet to see this same pace kept up by the company. With less growth than the indust...
Summary Exact Sciences is shifting its focus towards achieving positive adjusted EBITDA as a way to signal a path to eliminate cash burn. The company's long-term prospects look interesting with a pipeline spread across different timelines, including a MCED test and MRD testing. Whil...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world’s leading fundraising platform, Tariq is a distinguished marke...
The following slide deck was published by Guardant Health, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Guardant Health, Inc. 2022 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...